Furthermore, modulating cGAS-STING activity may offer therapeutic avenues for viral hepatitis and chronic liver diseases like MASLD and ALD, either by boosting antiviral responses or mitigating inflammation. The gene discussed is STING1; the disease is metabolic dysfunction-associated steatotic liver disease.